Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This pilot study examined whether gut microbiome disturbances, gut barrier dysfunction, bacterial translocation, and resulting inflammation are associated with cognitive dysfunction in dementia. Researchers assessed gut microbiome composition, gut barrier integrity, bacterial translocation markers, and inflammatory markers using stool and serum samples. Microbiome composition was profiled through 16S rRNA sequencing, with analysis performed using QIIME 2 and Calypso 7.14 tools. Nutritional status and medication use were also documented to characterize the study population.
Who was studied?
The study included 23 patients with dementia and 18 age and sex matched controls without cognitive impairment. Nutritional status was assessed in participants using the Mini Nutritional Assessment Short Form (MNA-SF). Detailed information on drug use was also collected from the cohort. This was a relatively small, matched case control pilot study rather than a large population based investigation.
What were the most important findings?
Dementia was associated with dysbiosis, reflected in differences in beta diversity and shifts in taxonomic composition of the gut microbiome compared to controls. Gut permeability was increased in dementia patients, as shown by elevated serum diamine oxidase (DAO) levels. Systemic inflammation was also confirmed, evidenced by increased soluble cluster of differentiation 14 levels. The abstract does not report findings specific to Faecalibacterium prausnitzii, butyrate, or anti-inflammatory commensals.
What are the greatest implications of this study?
These findings support the hypothesis that gut microbiome disturbances, impaired gut barrier function, and resulting systemic inflammation may contribute to cognitive dysfunction in dementia. The results suggest a potential gut-brain axis mechanism linking dysbiosis and barrier dysfunction to the inflammatory processes implicated in cognitive decline. As a pilot study with a modest sample size, these findings point toward the need for larger studies to confirm causal relationships and explore microbiome-targeted interventions for dementia.